Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study
Background: There is sufficient evidence of the high prevalence of obesity in schizophrenia (SZ) compared to the general population. Previous studies have reported that weight gain correlated with the response to antipsychotics in patients with SZ. Nonetheless, the relationship between body mass ind...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1264591/full |
| _version_ | 1827763946931617792 |
|---|---|
| author | Xiaofang Chen Yong Fan Wenchao Ren Maodi Sun Xiaoni Guan Meihong Xiu Shuyun Li Shuyun Li Shuyun Li |
| author_facet | Xiaofang Chen Yong Fan Wenchao Ren Maodi Sun Xiaoni Guan Meihong Xiu Shuyun Li Shuyun Li Shuyun Li |
| author_sort | Xiaofang Chen |
| collection | DOAJ |
| description | Background: There is sufficient evidence of the high prevalence of obesity in schizophrenia (SZ) compared to the general population. Previous studies have reported that weight gain correlated with the response to antipsychotics in patients with SZ. Nonetheless, the relationship between body mass index (BMI) and therapeutic benefits remains unclear. This study was designed to investigate the association between baseline BMI and improvements in clinical symptoms after treatment with antipsychotics in first-episode and medication-naïve SZ (FEMNS).Methods: A total of 241 FEMNS patients were enrolled and received risperidone over 12 weeks. The severity of symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS) and BMI was measured at baseline and 12-week follow-up.Results: We found that risperidone treatment raised the body weight of FEMNS patients and baseline BMI was negatively correlated with the improvement in negative symptoms (r = −0.14, p = 0.03) after 12-week treatment. Linear regression analysis indicated that baseline BMI was an independent predictor of response to risperidone in the early stage of SZ.Conclusion: The current study suggests a close relationship between baseline BMI and improvement in negative symptoms in SZ. |
| first_indexed | 2024-03-11T10:57:55Z |
| format | Article |
| id | doaj.art-18f3bda1ce864134a49dc53c4998c1a9 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-11T10:57:55Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-18f3bda1ce864134a49dc53c4998c1a92023-11-13T04:07:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-11-011410.3389/fphar.2023.12645911264591Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal studyXiaofang Chen0Yong Fan1Wenchao Ren2Maodi Sun3Xiaoni Guan4Meihong Xiu5Shuyun Li6Shuyun Li7Shuyun Li8Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical School, Beijing, ChinaQingdao Mental Health Center, Qingdao, ChinaQingdao Mental Health Center, Qingdao, ChinaNorth University of China, Taiyuan, ChinaBeijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical School, Beijing, ChinaBeijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical School, Beijing, ChinaDepartment of Nutritional and Metabolic Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, ChinaGuangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, ChinaKey Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, ChinaBackground: There is sufficient evidence of the high prevalence of obesity in schizophrenia (SZ) compared to the general population. Previous studies have reported that weight gain correlated with the response to antipsychotics in patients with SZ. Nonetheless, the relationship between body mass index (BMI) and therapeutic benefits remains unclear. This study was designed to investigate the association between baseline BMI and improvements in clinical symptoms after treatment with antipsychotics in first-episode and medication-naïve SZ (FEMNS).Methods: A total of 241 FEMNS patients were enrolled and received risperidone over 12 weeks. The severity of symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS) and BMI was measured at baseline and 12-week follow-up.Results: We found that risperidone treatment raised the body weight of FEMNS patients and baseline BMI was negatively correlated with the improvement in negative symptoms (r = −0.14, p = 0.03) after 12-week treatment. Linear regression analysis indicated that baseline BMI was an independent predictor of response to risperidone in the early stage of SZ.Conclusion: The current study suggests a close relationship between baseline BMI and improvement in negative symptoms in SZ.https://www.frontiersin.org/articles/10.3389/fphar.2023.1264591/fullschizophreniaweightimprovementsnegative symptomsrisperidone |
| spellingShingle | Xiaofang Chen Yong Fan Wenchao Ren Maodi Sun Xiaoni Guan Meihong Xiu Shuyun Li Shuyun Li Shuyun Li Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study Frontiers in Pharmacology schizophrenia weight improvements negative symptoms risperidone |
| title | Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study |
| title_full | Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study |
| title_fullStr | Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study |
| title_full_unstemmed | Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study |
| title_short | Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study |
| title_sort | baseline bmi is associated with clinical symptom improvements in first episode schizophrenia a longitudinal study |
| topic | schizophrenia weight improvements negative symptoms risperidone |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1264591/full |
| work_keys_str_mv | AT xiaofangchen baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT yongfan baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT wenchaoren baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT maodisun baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT xiaoniguan baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT meihongxiu baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT shuyunli baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT shuyunli baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy AT shuyunli baselinebmiisassociatedwithclinicalsymptomimprovementsinfirstepisodeschizophreniaalongitudinalstudy |